Long-term RNA interference gene therapy in a dominant retinitis pigmentosa mouse model.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22042849.
- Also identified by DOI 10.1073/pnas.1112758108 and PMC identifier 3215008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
RNA interference (RNAi) gene silencing is a potential therapeutic strategy for dominant retinal degeneration disorders. We used self-complementary (sc) AAV2/8 vector to develop an RNAi-based gene therapy in a dominant retinal degeneration mouse model expressing bovine GCAP1(Y99C). We established an in vitro shRNA screening assay based on EGFP-tagged bovine GCAP1, and identified a shRNA that effectively silenced the bovine GCAP1 transgene with ∼80% efficiency. Subretinal injection of scAAV2/8 carrying shRNA expression cassette showed robust expression as early as 1 wk after injection. The gene silencing significantly improved photoreceptor survival, delayed disease onset, and increased visual function. Our results provide a promising strategy toward effective RNAi-based gene therapy by scAAV2/8 delivery for dominant retinal diseases.
Medical subject headings
- Disease Models, Animal
- Genes, Dominant
- Genetic Therapy
- RNA Interference
- Retinitis Pigmentosa